There is no shortage of data, analysis, and opinion out there about the
virtues (or lack thereof) of spinoffs and corporate splits. They don't
always work, but I do believe that Agilent (NYSE: A )
will be one of those companies that benefits, as there really never
were meaningful synergies or counter-cyclical offsets between the test
and measurement operations and the life science tools and diagnostics
operations. Agilent still looks a little undervalued today and even with
the added cost burden of the split, the life science and diagnostic
operations in particular look well worth following.
Follow this link for more:
What You Need to Know About the Agilent Technologies Split
No comments:
Post a Comment